Russell Microcap Index, Program, QIDP, Absorption, HERE, Traction, CEO, Private Securities Litigation Reform Act, FDA, IPO, Minimum inhibitory concentration, Hand, Marketing, Patient, Infection, SMMT, Colon, Acrux, Ridinilazole, LLC, Optimism, Risk, Clinical trial, Kepler-86, Advertising, Daptomycin, Congress, NASDAQ, Stock dilution, Review, MIC, Death, Recurrence, Fast track (FDA), Goal, SEC, Research, HPM, Phase 3, Fine chemical, Risk management, Pharmaceutical industry, Antibiotics, Dietary supplement, Security (finance)
Monday, September 13, 2021 - 2:48pm
Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company
- Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
- Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
- Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
- Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.